All lobbying filings

EISAI INC.

Lobbying for EISAI INC.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · New Jersey · House · Senate · $520,000.00 expenses · posted Apr 21, 2025

Official filing document

Bills named in this filing 3

S 891
Bipartisan Health Care Act
HR 1968
Full-Year Continuing Appropriations and Extensions Act, 2025
HCONRES 14
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…

Lobbying activity 5

Health Issues

Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act(PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2026 National Defense Authorization Act; Pharmacy benefit managers (PBM) reform; S.891, Bipartisan Health Care Act, improvements to the 340B drug discount program.

Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. Issues related to pharmaceutical intellectual property.

Taxation/Internal Revenue Code

Issues related to tax reform. Issues related to Research and Development tax credit.

Trade (domestic/foreign)

Issues related to supply chain and tariffs.

Budget/Appropriations

H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4); H.Con.Res.14, FY2025 Budget Resolution; FY2025 Budget Reconciliation Process; all bio-pharmaceutical related provisions.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.